

Date: 13 March 2020

Re: Freedom of Information Request
Ref: 55- 2020

Thank you for your email dated the 14th February 2020, requesting information relating to patient treatment figures.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

- 1. How many patients with cutaneous squamous cell carcinoma have you treated [e.g. surgery, chemotherapy or radiotherapy] in the past 3 months?**
40
- 2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated [e.g. surgery, chemotherapy or radiotherapy] in the past 3 months?**
6
- 3. Of these how many are not candidates for curative surgery or curative radiation?**
Exempt under Section 40: Personal Information

4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following

- Libtayo (cemiplimab) – Exempt under Section 40: Personal Information
- Non curative surgery only – As our Trust is a tertiary specialist cancer treatment centre, we do not undertake surgery.
- Non curative surgery + chemotherapy* – As our Trust is a tertiary specialist cancer treatment centre, we do not undertake surgery.
- Non curative surgery + radiotherapy – As our Trust is a tertiary specialist cancer treatment centre, we do not undertake surgery.
- Non curative surgery + chemotherapy* + radiotherapy – As our Trust is a tertiary specialist cancer treatment centre, we do not undertake surgery.
- Chemotherapy* only - 0
- Chemotherapy* + radiotherapy - 0
- Non curative radiotherapy only – Exempt under Section 40: Personal Information
- No treatment - 0
- Palliative Care / Best Supportive care – Exempt under Section 40: Personal Information
- Other [please state]
**chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide*

5. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.
Yes, our Trust does treat adult multiple myeloma [MM]

6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following

**NB Please note the latest full month figures available are June to November 2019*

- Bortezomib [Velcade] – 17 (not as a single agent)
- Carfilzomib [Kyprolis] - 0
- Ixazomib [Ninlaro] – 20 (not as a single agent)
- Lenalidomide [Revlimid] – 61
- Daratumumab [Darzalex] - 9
- Melphalan, prednisolone and thalidomide (known as MPT) – Exempt under Section 40: Personal Information

- Cyclophosphamide, thalidomide and dexamethasone (known as CTD) - 8
- Pomalidomide [Imnovid] - Exempt under Section 40: Personal Information

7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

**NB Please note the latest full month figures available are June to November 2019*

27

If possible, how many CLL patients treated were new to therapy in the past 3 months?

The electronic prescribing system used to record treatment of CLL patients does not identify between new to therapy or existing therapy

8. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following

- Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR) - 0
- Bendamustine and rituximab (known as BR) - 0
- Ibrutinib [Imbruvica] - 21
- Chlorambucil - Exempt under Section 40: Personal Information
- Venetoclax - Exempt under Section 40: Personal Information
- Obinutuzumab - 0
- Idelalisib - 0
- Fludarabine and rituximab (known as FR) - 0
- High-dose prednisone and rituximab - 0
- Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) - 0
- Alemtuzumab (Campath) with rituximab - 0

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.